Department of Biology
Loyola University Maryland
4501 North Charles Street
Baltimore, MD 21210-2699
Office: DS 376
Office tel: 410-617-2139
Areas of Interest: Cancer Biology and Drug Resistance
I am currently doing breast cancer research whose overall goal is to understand the mechanisms involved in drug resistance in breast cancer and developing novel therapies that either prevent resistance from occurring or treat the resistant cancer. Within this goal, I am 1) studying factors that may be involved in drug resistant cancer and could be used as potential biomarkers for patient screening and as potential therapeutic targets; 2) studying association between drug resistance and cancer stem cells; and 3) studying the potential of using microRNAs as diagnositic tools for predicting drug resistance in cancer patients.
Molitoris KH, Kazi AA, Koos RD. Inhibition of oxygen-induced hypoxia-inducible factor-1alpha degradation unmasks estradiol induction of vascular endothelial growth factor expression in ECC-1 cancer cells in vitro. Endocrinology. 2009 Dec;150(12):5405-14. Epub 2009 Oct 9.
Kazi AA, Molitoris KH, Koos RD.Estrogen rapidly activates the PI3K/AKT pathway and hypoxia-inducible factor 1 and induces vascular endothelial growth factor A expression in luminal epithelial cells of the rat uterus. Biol Reprod. 2009 Aug;81(2):378-87. Epub 2009 May 6.
Kazi AA, Koos RD. Estrogen-induced activation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor expression, and edema in the uterus are mediated by the phosphatidylinositol 3-kinase/Akt pathway. Endocrinology. 2007 May;148(5):2363-74. Epub 2007 Feb 1.